This Investor Sold $104 Million of Nuvalent Stock Amid Cancer Drug Developer's Nearly 30% Rally

AI Briefing

• – Nuvalent's stock price surged 29.7% in the past year.
• – The company's stock rose amid its cancer drug development progress.
• – The sale of $104 million of stock was made by an investor.